Loading…
This event has ended. Visit the official site or create your own event on Sched.
Back To Schedule
Thursday, June 30 • 10:45am - 12:00pm
#410: The Role of Big Data in Transforming the Detection of Adverse Drug Reactions

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Limited Capacity seats available
Component Type: Session
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-16-579-L04-P; CME 1.25; IACET 1.25; RN 1.25

This session will provide an overview of ongoing initiatives at government, industry, and academic sites on leveraging Big Data for adverse drug reactions detection.


Learning Objectives

Discuss how Big Data can improve the detection of adverse drug reactions; Identify the data sources that will likely to be part of the Big Data paradigm envisioned for pharmacovigilance; Define the strengths, limitations, and challenges associated with the use of each of the identified data sources for improving the detection of adverse drug reactions.

Chair

Rave Harpaz, PhD

Speaker

Harnessing Scientific Literature Reports for Pharmacovigilance: FDA Perspective
Alfred Sorbello, DO, MPH

Maximizing Data Sources for Signal Detection: Pharmaceutical Company Perspective
Amy Purrington, MD

Social Media Mining for Public Health Monitoring and Surveillance
Graciela Gonzalez Hernandez, PhD


Chair
avatar for Rave Harpaz

Rave Harpaz

Senior Research Scientist, Oracle Health Sciences
Rave Harpaz is a Senior Research Scientist at Oracle Health Sciences. Previously, Rave was a Research Scientist at Stanford University, a post-doctoral fellow at Columbia University, and a quantitative risk modeling analyst at Merrill Lynch. Rave holds a PhD in Computer Science from... Read More →

Speakers
GG

Graciela Gonzalez Hernandez

Associate Professor, Department of Biomedical Informatics, Arizona State University
avatar for Amy Purrington

Amy Purrington

Head, Signal Management Group, Janssen Pharmaceuticals, Inc.
Amy is an experienced pharmacovigilance physician, focusing on proactive surveillance. She has been in industry for 15 years and at JNJ for the last 12. She is currently the lead of the Signal Management Group, which is dedicated to the development and implementation of new signal... Read More →
avatar for Alfred Sorbello

Alfred Sorbello

Medical Officer, Office of Translational Sciences, CDER, FDA
Dr. Alfred Sorbello is a Medical Officer at FDA in the Office of Translational Sciences of the Center for Drug Evaluation and Research (CDER). Previously, he worked in CDER’s Office of Surveillance and Epidemiology /Division of Pharmacovigilance II and in CDER’s Office of New... Read More →

Thursday June 30, 2016 10:45am - 12:00pm EDT
113B Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
  Trk 14: Clin Safety-PV, Session